



Product: apo-Transferrin Human Powder

Catalog #: 800-130P

Lot #: H021040

Origin: United States (100%)

Manufacture Date: Jan 2021

Expiration Date: Jan 2026

TEST	METHODOLOGY	SPECIFICATION	RESULTS
Biological Testing			
Bioburden		<10 cfu/mL	Pass
Endotoxin	LAL	≤1 EU/mg	< 0.05 EU/mg
Microbiological Testing			
Mycoplasma		Not Detected	Not Detected
Viral Testing			
HBsAg		Non-Reactive	Non-Reactive
Anti-HCV		Non-Reactive	Non-Reactive
Anti-HIV-1/HIV-2		Non-Reactive	Non-Reactive
ALT		Negative	Negative
Syphilis		Negative	Negative
HBV-NAT		Non-Reactive	Non-Reactive
HIV-NAT		Non-Reactive	Non-Reactive
HAV-NAT		Non-Reactive	Non-Reactive
HCV-NAT		Non-Reactive	Non-Reactive
Parvo B19-NAT		Non-Reactive	Non-Reactive
Physical Testing			
Appearance		Report	White Crystalline Powder
pH @ RT, 3% Solution		6.5-8.0	7.17
Moisture		≤5.0%	0.83%
Solubility		Readily Soluble at 1% in De-ionized water	Pass
Optical density		Report	10.2
Biochemical Testing			
Purity	Cellulose Acetate Electrophoresis	≥98% of total protein	Pass
Protein Analysis		>98%	103%
SDS-Polyacrylamide Gel		Conforms	Pass
Iron Estimated ICP		< 50 ppm	6 ppm

Product: apo-Transferrin Human Powder

Catalog #: 800-130P

Lot #: H021040

Origin: United States (100%)

Manufacture Date: Jan 2021

Expiration Date: Jan 2026

Results shown were obtained by carefully performed methods believed to be reliable. However, since some results may vary for specific tests depending upon methodology and other variables, it is suggested that tests for which results are particularly important be repeated by the user of this product.

All human blood products are collected from stringently screened donors at FDA-licensed collection centers in the United States. All donors are tested and found to be negative for Indirect Antiglobulin

Single homogenous batch, heat treated at 62 \pm 2 $^{\circ}$ C for 10 hours and lyophilized from approximately 0.02M NH₄HCO₃. May contain traces of buffer salts. Dispensed by dry weight.

Store at 2-8 $^{\circ}$ C. Allow temperature to equilibrate to room temperature prior to use.

Julianne Wilson / 29 SEP 2021
Created By/ Date

[Signature] / 29 SEP 2021
Verified By/ Date